Latest Period
Q1 2026
Security Snapshot
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) Institutional Ownership
CUSIP: 64136E102
13F Institutional Holders and Ownership History from Q4 2024 to Q2 2026
Institutions Reporting
19
Shares (Excl. Options)
1,757,860
Price
$4.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- NEUP on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 1,757,860
- Total 13F value
- $7,153,657
- Portfolio coverage rank
- 0%
- Share change
- +180,706
- Value change
- +$756,052
- Number of holders
- 19
- Shares outstanding
- 5,420,049
- SEC-reported price per share
- $4.34
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 64136E102.
- 19 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 19 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,153,657 to $115,000.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 19 institutions filings for Q1 2026.
Security key
64136E102
Latest holder period
Q1 2026
13F holders
19
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
NEUP full holder history
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Neuphoria Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 64136E102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
NEUP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | $5,365,401 | 1,033,796 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Lynx1 Capital Management LP | 16% | 0% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| Baselake Partners, LP | 4.1% | -59% | $862,110 | 222,222 | 0% | Baselake Partners, LP | 31 Dec 2025 | |
| Shay Capital LLC | 7.3% | $2,035,520 | 171,629 | Shay Capital LLC | 24 Oct 2025 | |||
| Coastlands Capital LP | 5.1% | $1,423,200 | 120,000 | Coastlands Capital LP | 05 Nov 2025 | |||
| Apeiron Investment Group Ltd. | 4.5% | $376,887 | 72,618 | Apeiron Investment Group Ltd. | 24 Jan 2025 |
As of 31 Mar 2026, 19 institutional investors reported holding 1,757,860 shares of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP). This represents 32% of the company’s total 5,420,049 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
32%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 16% | 875,328 | +0.01% | 0.56% | $3,562,585 |
| AdvisorShares Investments LLC | 2.9% | 155,367 | +16% | 0.12% | $632,344 |
| Shay Capital LLC | 2.8% | 151,010 | -11% | 0.09% | $614,611 |
| Balyasny Asset Management L.P. | 2.6% | 142,183 | 0% | $578,685 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 98,516 | 0% | 0% | $400,960 |
| Squadron Capital Management LLC | 1.4% | 76,728 | 0.12% | $312,283 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.96% | 52,007 | +201% | 0% | $211,668 |
| Ikarian Capital, LLC | 0.88% | 47,443 | 0% | 0.03% | $193,093 |
| VANGUARD FIDUCIARY TRUST CO | 0.62% | 33,589 | 0% | 0% | $136,707 |
| ADAR1 Capital Management, LLC | 0.55% | 30,000 | 0% | 0.01% | $122,100 |
| FNY Investment Advisers, LLC | 0.49% | 26,500 | 0% | 0.05% | $107,000 |
| CITADEL ADVISORS LLC | 0.36% | 19,331 | 0% | $78,677 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.26% | 14,000 | 0% | 0% | $56,980 |
| Virtu Financial LLC | 0.22% | 12,033 | 0% | $49,000 | |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.21% | 11,222 | +0.13% | 0% | $45,670 |
| Merck & Co., Inc. | 0.18% | 10,027 | 0% | 0.01% | $40,810 |
| UBS Group AG | 0.04% | 2,316 | +40% | 0% | $9,426 |
| RHUMBLINE ADVISERS | 0% | 202 | 0% | 0% | $822 |
| MORGAN STANLEY | 0% | 58 | 0% | 0% | $236 |
| XTX Topco Ltd | 0% | 0 | -100% | $0 | |
| JANE STREET GROUP, LLC | 0% | 0 | -100% | $0 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0% | 0 | -100% | $0 | |
| Tower Research Capital LLC (TRC) | 0% | 0 | -100% | $0 | |
| DIADEMA PARTNERS LP | 0% | 0 | -100% | $0 | |
| Persistent Asset Partners Ltd | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 26,500 | $115,000 | $4.34 | 1 | |
| 2026 Q1 | 1,757,860 | $7,153,657 | +$756,052 | $4.07 | 19 |
| 2025 Q4 | 1,465,999 | $5,687,252 | +$4,548,427 | $3.88 | 21 |
| 2025 Q3 | 195,338 | $2,303,036 | +$535,083 | $11.79 | 15 |
| 2025 Q2 | 177,963 | $1,263,538 | +$105,431 | $7.10 | 9 |
| 2025 Q1 | 163,114 | $935,356 | +$529,238 | $5.76 | 7 |
| 2024 Q4 | 79,719 | $273,435 | +$239,042 | $3.43 | 7 |